An AARP report reveals prices for brand name prescription drugs most commonly used by older patients has risen nearly twice the rate of inflation during the second quarter

A collaboration of 24 leading human geneticists will look at TB, heart disease, type 1 and 2 diabetes, arthritis, Crohn's disease, ulcerative colitis, bipolar disorder and hypertension, in hopes to gain a better understanding of who is at risk, and the development of new treatments.

Researchers in the Wellcome Trust Case Control Consortium (WTCCC) will analyze over 19,000 DNA samples - 2,000 from patients with each disease, which will be compared with 3,000 samples from healthy people to identify the genetic differences between them

A collaboration of 24 leading human geneticists will look at TB, heart disease, type 1 and 2 diabetes, arthritis, Crohn's disease, ulcerative colitis, bipolar disorder and hypertension, in hopes to gain a better understanding of who is at risk, and the development of new treatments.

Researchers in the Wellcome Trust Case Control Consortium (WTCCC) will analyze over 19,000 DNA samples - 2,000 from patients with each disease which will be compared with 3,000 samples from healthy people to identify the genetic differences between them

The Food and Drug Administration (FDA) approves a new biologic treatment to treat ulcerative colitis. Manufacturer Centocor, Inc. announces that Remicade has received the green light to treat the chronic inflammatory bowel disease.

Remicade's efficiency in the treatment of inflammatory bowel disease is well established. It was first approved in the United States for the treatment of Crohn's disease in 1998.Remicade remains to this day the only anti-tumor necrosis factor therapy indicated for the treatment of Chron's. With this new approval for the treatment of ulcerative colitis, Remicade is now the only biologic indicated for the treatment of both types of inflammatory bowel diseases

The Food and Drug Administration (FDA) approves a new biologic treatment to treat ulcerative colitis. Manufacturer Centocor, Inc. announces that Remicade has received the green light to treat the chronic inflammatory bowel disease.

Remicade's efficiency in the treatment of inflammatory bowel disease is well established. It was first approved in the United States for the treatment of Crohn's disease in 1998.Remicade remains to this day the only anti-tumor necrosis factor therapy indicated for the treatment of Chron's. With this new approval for the treatment of ulcerative colitis, Remicade is now the only biologic indicated for the treatment of both types of inflammatory bowel diseases